|
|
103 Carnegie Center
Princeton, NJ 08540 USA
phone:(609) 853 0100
fax:(609) 275 6155
|
|
| Symbol |
STNT.PA |
| Exchange |
EuroNext Paris |
| Founded |
2006 |
| Employees |
18 |
|
|
| www.stentys.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Breakthrough treatment of Acute Myocardial Infarction |
|
| Management |
| Gonzague Issenmann, Chief Executive Officer; Stanislas Piot, Chief Financial Officer; Hikmat Hojeibane, Chief Technology Officer; Rene Spaargaren, MD, Chief Medical Officer; Luc Morisset, Director Regulatory Affairs; Paul Geudens, VP Sales & Marketing; Benoit Vandenbossche, Director Operations |
| |
|
|
|
|
|
|
| Recent Results |
| Stentys announced in May 2009 that it has established U.S. operations in Princeton, N.J., where the Company will focus its R&D efforts. The Princeton operation will be the cornerstone of the Companys efforts when seeking FDA clearance to market its self-expanding and disconnectable stent platform. |
| |
|
|
|
|
| Keywords |
| cardiology, coronary, acute myocardial infarction, AMI, stent, DES, bifurcation |
|
|
|
| Description |
|
STENTYS offers simple, innovative solutions to interventional cardiologists when treating the challenging disease of their patients. When dealing with acute myocardial infarction or coronary artery disease close to a side branch, the STENTYS platform provides an efficient and elegant new treatment approach that does not demand any specific training and assures long term clinical results for patients. |
|
| Products / Services |
The STENTYS self-apposing stent is available in bare and drug-eluting (paclitaxel) forms.
|
|
| Technology / Differentiation |
| Conventional balloon-expandable stents may have a higher risk of thrombosis in AMI patients due to malapposition as a result of stent recoil, vasodilation and thrombus dissolution after the procedure. The STENTYS self-apposing stent may provide a safer option for the treatment of AMI patients by gently expanding to tailor its size to that of the vessel to reduce malapposition and thus minimise the thrombotic risk. The STENTYS stent also provides the ability to disconnect the stent connectors anywhere along the stent (apart from the first and last 2 rows), enabling the operator to create a custom opening to a side branch if necessary, without the need for precise initial stent placement. |
|
| Market / Customers |
The market for the company's self-apposing stent platform is approximately $2.3 billion. The market for AMI stents, which represents about one third of PCIs today thanks to clinical evidence that primary PCI is superior to thrombolytic drug therapy, is expected to continue growing as hospitals and emergency care units across the world improve systems for transfering patients to cath labs.
|
|
| Funding |
| STENTYS successfully completed an IPO on NYSE EuroNext in Paris in October 2010 and raised $31.9m. |
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members